Groundbreaking research from Harvard and other institutions reveals critical links between brain lithium deficiency and Alzheimer’s disease pathology. Studies demonstrate that lithium naturally occurs in the brain to support neuronal health and that binding of amyloid plaques reduces lithium levels, exacerbating neurodegeneration. Novel amyloid-evading lithium compounds effectively reverse Alzheimer’s pathology and restore memory in mouse models, suggesting new therapeutic avenues. Similarly, selective adrenergic receptor targeting by new non-opioid analgesics shows promise for safer pain management.